🚀 VC round data is live in beta, check it out!
Betta Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Betta Pharmaceuticals and similar public comparables like Celldex Therapeutics, Soleno Therapeutics, Disc Medicine, Hisamitsu Pharmaceutical and more.
Betta Pharmaceuticals Overview
About Betta Pharmaceuticals
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Founded
2003
HQ
Employees
N/A
Website
Financials (LTM)
EV
$3B
Betta Pharmaceuticals Financials
Betta Pharmaceuticals reported last 12-month revenue of $553M.
In the same LTM period, Betta Pharmaceuticals generated $452M in gross profit and $93M in net income.
Revenue (LTM)
Betta Pharmaceuticals P&L
In the most recent fiscal year, Betta Pharmaceuticals reported revenue of $424M and EBITDA of $150M.
Betta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $553M | XXX | $424M | XXX | XXX | XXX |
| Gross Profit | $452M | XXX | $345M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | $150M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $93M | XXX | $59M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $173M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Betta Pharmaceuticals Stock Performance
Betta Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Betta Pharmaceuticals' stock price is $6.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBetta Pharmaceuticals Valuation Multiples
Betta Pharmaceuticals trades at 5.4x EV/Revenue multiple, and 20.0x EV/EBITDA.
EV / Revenue (LTM)
Betta Pharmaceuticals Financial Valuation Multiples
As of April 20, 2026, Betta Pharmaceuticals has market cap of $3B and EV of $3B.
Equity research analysts estimate Betta Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Betta Pharmaceuticals has a P/E ratio of 29.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBIT | 31.7x | XXX | 41.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 29.1x | XXX | 46.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 244.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Betta Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Betta Pharmaceuticals Margins & Growth Rates
Betta Pharmaceuticals' revenue in the last 12 month grew by 22%.
Betta Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 19% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Betta Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Betta Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Soleno Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Kodiak Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Betta Pharmaceuticals M&A Activity
Betta Pharmaceuticals acquired XXX companies to date.
Last acquisition by Betta Pharmaceuticals was on XXXXXXXX, XXXXX. Betta Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Betta Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBetta Pharmaceuticals Investment Activity
Betta Pharmaceuticals invested in XXX companies to date.
Betta Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Betta Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Betta Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Betta Pharmaceuticals
| When was Betta Pharmaceuticals founded? | Betta Pharmaceuticals was founded in 2003. |
| Where is Betta Pharmaceuticals headquartered? | Betta Pharmaceuticals is headquartered in China. |
| Who is the CEO of Betta Pharmaceuticals? | Betta Pharmaceuticals' CEO is Lieming Ding. |
| Is Betta Pharmaceuticals publicly listed? | Yes, Betta Pharmaceuticals is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Betta Pharmaceuticals? | Betta Pharmaceuticals trades under 300558 ticker. |
| When did Betta Pharmaceuticals go public? | Betta Pharmaceuticals went public in 2016. |
| Who are competitors of Betta Pharmaceuticals? | Betta Pharmaceuticals main competitors are Celldex Therapeutics, Soleno Therapeutics, Disc Medicine, Hisamitsu Pharmaceutical. |
| What is the current market cap of Betta Pharmaceuticals? | Betta Pharmaceuticals' current market cap is $3B. |
| What is the current revenue of Betta Pharmaceuticals? | Betta Pharmaceuticals' last 12 months revenue is $553M. |
| What is the current revenue growth of Betta Pharmaceuticals? | Betta Pharmaceuticals revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Betta Pharmaceuticals? | Current revenue multiple of Betta Pharmaceuticals is 5.4x. |
| Is Betta Pharmaceuticals profitable? | Yes, Betta Pharmaceuticals is net-income-positive (as of the last 12 months). |
| What is the current net income of Betta Pharmaceuticals? | Betta Pharmaceuticals' last 12 months net income is $93M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.